Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Genitourinary Cancers Symposium reaches beyond the latest prostate, bladder and kidney cancer treatments.
Men who took Zytiga had higher quality of life scores and less pain than those treated with chemotherapy.
MK-6482 shrank tumors in 24% of people with advanced renal cell carcinoma.
The personalized vaccine was associated with a 45% lower risk of death in a real-world study.
Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.